Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Earnings Call Transcript

Page 5 of 5

Dr. Kristen Buck: No, you are correct, Dave. And we have procured the cisplatin to be able to supply our Bolster trial.

Operator: This concludes the question-and-answer session. I’ll turn the call back to Dr.Mazzo for closing remarks.

Dr. David Mazzo: Well, again, thank you all for participating in today’s call. We look forward to speaking with you again during our next quarterly conference call and to continuing to provide updates on our achievements and progress. We remain grateful for your continued interest and support. Stay well, and have a great day.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Lisata Therapeutics Inc. (NASDAQ:LSTA)

Page 5 of 5